Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya

This study has been completed.
Sponsor:
Collaborators:
Kenya Medical Research Institute
Kenya Ministry of Health
Information provided by (Responsible Party):
Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier:
NCT00130065
First received: August 12, 2005
Last updated: September 26, 2012
Last verified: September 2012

August 12, 2005
September 26, 2012
November 2003
February 2006   (final data collection date for primary outcome measure)
  • Peripheral parasitemia
  • Hemoglobin level
Same as current
Complete list of historical versions of study NCT00130065 on ClinicalTrials.gov Archive Site
Effect of HIV serostatus on drug efficacy
Same as current
Not Provided
Not Provided
 
The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya
The Effect of Folic Acid Supplementation on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya

The purpose of this study is to determine whether folic acid, which is often routinely given to pregnant women to prevent birth defects and anemia, affects the efficacy of sulfadoxine-pyrimethamine, another drug that is routinely given to pregnant women in highly malarious areas, for prevention of the adverse effects of malaria during pregnancy.

In malaria endemic areas in sub-Saharan Africa, pregnant women, especially primi- and secundi-gravidae, are more likely to have placental and peripheral parasitemia with Plasmodium falciparum than non-pregnant women. Adverse consequences of malaria in pregnancy include maternal anemia, and low birth weight of the new born. Low birth weight is known to be the most important risk factor for infant mortality.

Intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) during pregnancy can mitigate the adverse effects of malaria in pregnancy and is the current standard of care in areas of high malaria transmission in sub-Saharan Africa, as recommended by the World Health Organization.

SP acts by inhibiting parasite enzymes in the metabolism of folic acid. However, in vitro studies indicate that folic acid can antagonize the antimalarial parasite activity of SP. Furthermore, in one West African study, supplementary folic acid compromised the antimalarial efficacy of SP in children with acute malaria aged 6 months to 12 years.

Folic acid requirements are increased during pregnancy, and supplementation with folic acid in pregnancy is recommended. Although in most countries a daily supplementation of 400 to 600 micrograms is considered sufficient, for logistical reasons the daily recommended dose in Kenya is 5 mg of folic acid during pregnancy. It is unknown whether folic acid supplementation might compromise the efficacy of IPT with SP in pregnant women living in malaria endemic areas.

Several studies have shown that HIV-seropositive pregnant women have a higher risk of malaria than HIV-seronegative pregnant women. In addition, HIV-infected women are more likely to be anemic compared with HIV-uninfected women. A few studies have also shown that HIV-seropositive women do not appear to respond as well to IPT with SP compared to HIV-seronegative pregnant women.

In a recent study in pregnant women in Zimbabwe, HIV-infection was a negative predictor of serum folate, and the authors suggested this may be because of reduced intake and absorption, and increased catabolism in HIV-infected pregnant women. Because HIV-seropositive women as a group may have a different folic acid status (and a potential different reaction to folic acid supplementation) than HIV-seronegative women, it is important to assess HIV-status in study participants. It is also important to confirm that no difference exists between HIV-seropositive and HIV-seronegative women in efficacy of SP for clearance of peripheral parasitemia.

Comparison: Parasitemic pregnant women are randomized to receive either SP with folic acid 5 mg, or SP with folic acid 0.4 mg, or SP and placebo. The placebo and the folic acid 0.4 mg are given for two weeks, and then are replaced by folic acid 5 mg.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Malaria
  • Drug: Sulfadoxine-pyrimethamine/folic acid
  • Drug: Sulfadoxine-pyrimethamine/placebo
Not Provided
van Eijk AM, Ouma PO, Williamson J, Ter Kuile FO, Parise M, Otieno K, Hamel MJ, Ayisi JG, Kariuki S, Kager PA, Slutsker L. Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western kenya who have uncomplicated malaria. J Infect Dis. 2008 Nov 15;198(10):1550-3.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
600
February 2006
February 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Parasitemia with a parasite density of ≥ 500 parasites/microliter
  • Gestational age > 16 weeks and < 35 weeks
  • Willingness to provide blood samples and participate in HIV counseling and testing
  • Available for follow up for the entire study period
  • Hemoglobin > 7 g/dl
  • Age 15-45 years

Exclusion Criteria:

  • Use of folate in the last 4 weeks
  • Gestational age <16 weeks or >35 weeks
  • History of an allergy to sulfonamides or other unknown drugs
  • Intake of sulfa-containing drugs or 4-aminoquinolones in the previous month
  • A urine test positive for sulfa-compounds
  • Sickle cell disease
  • Concomitant diseases needing treatment with co-trimoxazole or other sulfa-containing drug
  • Hemoglobin < 7 g/dl
  • Severe malaria or any other serious medical condition requiring hospitalization and/or additional treatment. Clinical danger signs of severe malaria include prostration, impaired consciousness, respiratory distress, multiple convulsions, circulatory collapse, pulmonary oedema, abnormal bleeding, jaundice, and hemoglobinuria. Laboratory signs of severe malaria include severe anemia (hemoglobin < 7 g/dl), hypoglycemia, acidosis, hyperlactataemia, hyperparasitaemia (a parasitemia > 100,000 parasites/µl), and renal impairment
Female
15 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
Kenya
 
NCT00130065
CDC-NCID-3683, UR6-CCU018970
Not Provided
Centers for Disease Control and Prevention
Centers for Disease Control and Prevention
  • Kenya Medical Research Institute
  • Kenya Ministry of Health
Principal Investigator: Annemieke Van Eijk, M.D., Ph.D. Centers for Disease Control and Prevention, Kenya Medical Research Institiute
Principal Investigator: Monica Parise, M.D. Centers for Disease Control and Prevention
Principal Investigator: Laurence Slutsker, M.D. Centers for Disease Control and Prevention, Kenya Medical Research Institute
Centers for Disease Control and Prevention
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP